Clinical Trial Update: Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tolerability and immunogenicity of Gardasil in females aged 16-23 in India was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HPV Infections | Phase 3 | Status: WITHDRAWN